Literature DB >> 8323529

Angiotensin III is a new chemoattractant for polymorphonuclear leukocytes.

Y Yamamoto1, T Yamamguchi, M Shimamura, T Hazato.   

Abstract

To clarify the role of angiotensin III (ANGIII) in inflammation, we examined the effect of ANGIII on the chemotaxis of human polymorphonuclear neutrophils (PMNs). The elicitation of PMN chemotaxis by ANGIII was dose dependent with an optimum dose of 10(-10) M. The time course for ANGIII-elicited chemotaxis showed a maximal level at 90 min, but N-formyl-Met-Leu-Phe (FMLP) elicited a maximal level of chemotaxis at 60 min. When ANGIII (10(-10) M) and FMLP (10(-7) M) were given in combination, the level of chemotaxis elicited was not significantly different from the levels attained with each peptide alone, suggesting that a similar pathway of signal transduction might be involved in the chemotaxis of PMNs elicited by ANGIII and FMLP. Thus, ANGIII is a new chemoattractant for PMNs that may use a signal transduction pathway similar to, but different from, that used by FMLP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8323529     DOI: 10.1006/bbrc.1993.1729

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.

Authors:  K Morgan
Journal:  Br Heart J       Date:  1994-09

3.  Angiotensin III increases monocyte chemoattractant protein-1 expression in cultured human proximal tubular epithelial cells.

Authors:  Hyung Wook Kim; Young Ok Kim; Sun Ae Yoon; Jeong-Sun Han; Hyun-Bae Chun; Young Soo Kim
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.